

K 06 2262

 A Novartis Company	CIBA Vision® Corporation 11460 Johns Creek Parkway Duluth, Georgia USA 30097	3-Aug-2006 Page 1 of 4 v01
Sifilcon A Soft Contact Lenses for Daily Wear 510(k) Summary of Safety and Substantial Equivalence		

510(k) Summary

1. Submitter Information:

NOV 14 2006

Company: CIBA Vision Corporation
11460 Johns Creek Parkway
Duluth, Georgia USA 30097

Contact Person: Alicia M. Plesnarski, RAC
Director, Global Regulatory Affairs
alicia.plesnarski@cibavision.com

Telephone: 678-415-3924
FAX: 678-415-3454
Date Prepared: 3 August 2006

2. Device Name:

- Common Name: Soft Contact Lens
- Trade/Proprietary Name: CIBA Vision® (sifilcon A)
- Classification Name: Daily Wear Soft Contact Lens
- Device Classification: Class II [21 CFR 886.5925 (b) (1)]

3. Predicate Device:

CIBA Vision's (Iotraficon B) soft contact lenses. Both Iotraficon B (predicate) and sifilcon A are in FDA Group 1 (low water, nonionic polymer). CIBA Vision obtained FDA 510(k) clearance for (Iotraficon B) lenses for daily wear on March 12, 2004 (K033919).

4. Description of Device:

The lens material is 32% water and 68% sifilcon A, a fluoro-silicone containing hydrogel which is surface treated.

Sifilcon B lens designs include spherical, toric, multifocal and multifocal toric in the following parameter ranges:

- Diameter Range: 12.0 to 15.0 mm
- Base Curve Range: 7.0 to 9.2 mm
- Power Range: -20.00D to +20.00D
- Center Thickness: 0.070 mm for -3.00D spherical (varies with power)

Lenses contain the color additive Phthalocyanine Green (PCN Green), a light green handling tint, which makes them easier to see when handling.

 <p>CIBA Vision A Novartis Company</p>	<p>CIBA Vision® Corporation 11460 Johns Creek Parkway Duluth, Georgia USA 30097</p>	<p>3-Aug-2006 Page 2 of 4 v01</p>
<p>Sifilcon A Soft Contact Lenses for Daily Wear 510(k) Summary of Safety and Substantial Equivalence</p>		

Lenses have the following properties:

- Refractive index: 1.43 (hydrated)
- Light transmittance: approximately 92 %
- Water content : 32% by weight in normal saline
- Oxygen permeability 82×10^{-11}
 $[(\text{cm}^2 / \text{sec})(\text{ml O}_2 / \text{ml} \cdot \text{mmHg})]$
measured at 35°C (intrinsic Dk-Polarographic method)

Lenses are supplied sterile in sealed blister-packs containing isotonic phosphate buffered saline solution. The compatibility and package integrity of the blister-pack packaging system has been demonstrated and successfully used for other CIBA Vision marketed lens products, and packaged lenses are effectively steam sterilized in a validated autoclave. Blister-pack containers are labeled with the lens parameters, lot number and product expiration date. The expiration date has been established through stability studies that have assessed the chemical stability of the lens and package integrity (ability to maintain sterility). Shelf-life studies are ongoing to establish and extend the labeled expiration date.

5. Indications for Use:

CIBA Vision® (sifilcon A) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who have 1.50 diopters or less of astigmatism.

CIBA Vision® Toric (sifilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who have 10.00 diopters (D) or less of astigmatism.

CIBA Vision® Multifocal (sifilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) and/or presbyopia in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +4.00 diopters (D) or less and who have 1.50 diopters or less of astigmatism.

CIBA Vision® Multifocal Toric (sifilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia, hyperopia, astigmatism and presbyopia) in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +4.00 diopters (D) or less and have 10.00 diopters (D) or less of astigmatism.

The lenses may be prescribed for daily wear with removal for cleaning and disinfection (chemical, not heat) prior to reinsertion, as recommended by the eye care professional.

6. Description of Safety and Substantial Equivalence:

A series of non-clinical tests and a clinical study were performed to demonstrate the substantial equivalence of the device to the predicate device. All testing was conducted in

 <p>CIBA Vision A Novartis Company</p>	<p>CIBA Vision® Corporation 11460 Johns Creek Parkway Duluth, Georgia USA 30097</p>	<p>3-Aug-2006 Page 3 of 4 v01</p>
<p>Sifilcon A Soft Contact Lenses for Daily Wear 510(k) Summary of Safety and Substantial Equivalence</p>		

accordance with the May 1994 FDA guideline titled *Premarket Notification 510(k) Guidance Document for Class II Contact Lenses* and in conformance to applicable device regulations. Results verify that sifilcon A lenses have material characteristics comparable to or better than other currently marketed soft contact lenses, are compatible with commonly available lens care products and are non-toxic and biocompatible. Clinically, the lens performed satisfactorily in a daily wear investigation. Results from all tests demonstrate the substantial equivalence to a previously FDA approved predicate (control) lenses.

Non-clinical Testing:

A series of non-clinical testing was performed to verify equivalence of the device to the predicate device. Non-clinical biocompatibility testing was conducted in accordance with the GLP regulation (21 CFR Part 58).

The results of all non-clinical testing on (sifilcon A) contact lens demonstrate:

- Lens physical and material properties of the device are consistent with or better than industry marketed lenses, and substantially equivalent to the predicate lens.
- The lens material is compatible with commonly available lens care products.
- The lens material and extracts of the device are substantially equivalent to the predicate device and are non toxic and non-irritating.

Clinical Testing:

The sifilcon A contact lens was investigated in daily wear clinical study. The three-month clinical evaluation was conducted in accordance with current Good Clinical Practices and published regulations (21 CFR Parts 50, 56, 312, and 812). The study assessed the clinical performance of the lenses as compared to an FDA approved and commercially available contact lens.

Clinical evaluation of the sifilcon A lens demonstrated similar overall performance in the clinically relevant areas of vision, health, comfort and fit as compared to the control lens when used under daily wear conditions.

 A Novartis Company	CIBA Vision® Corporation 11460 Johns Creek Parkway Duluth, Georgia USA 30097	3-Aug-2006 Page 4 of 4 v01
Sifilcon A Soft Contact Lenses for Daily Wear 510(k) Summary of Safety and Substantial Equivalence		

Substantial Equivalence:

The CIBA Vision (sifilcon A) contact lens is substantially equivalent to the predicate lens and similar to other daily wear soft contact lenses in terms of water content (32% water) and ionic characteristics (FDA Group I: low water, nonionic), clinical performance, and indications for use. In addition, the lenses may be disinfected using a chemical, not heat, disinfection regimen.

Any differences which may exist between the sifilcon A soft contact lens and other Group I soft hydrophilic contact lenses do not adversely affect the safety and effectiveness of the device.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

NOV 14 2006

Ciba Vision Corporation
c/o Alicia M. Plesnarski, RAC
11460 Johns Creek Parkway
Duluth, GA 30097

Re: K062262
Trade/Device Name: Ciba Vision® (sifilcon A) Soft Contact Lenses for Daily Wear
Regulation Number: 21 CFR 886.5925
Regulation Name: Soft (hydrophilic) contact lenses
Regulatory Class: Class II
Product Code: LPL
Dated: October 19, 2006
Received: October 20, 2006

Dear Ms. Plesnarski:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic and Ear, Nose
and Throat Devices

Office of Device Evaluation

Center for Devices and
Radiological Health

Enclosure

PART II. INDICATIONS FOR USE STATEMENT

510(k) Number:

K062262

Device Name:

CIBA Vision® (sifilcon A) Soft Contact Lenses

Indications For Use:

CIBA Vision® (sifilcon A) spherical soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who have 1.50 diopters or less of astigmatism.


CIBA Vision® Toric (sifilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who have 10.00 diopters (D) or less of astigmatism.

CIBA Vision® Multifocal (sifilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia and hyperopia) and/or presbyopia in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +4.00 diopters (D) or less and who have 1.50 diopters or less of astigmatism.

CIBA Vision® Multifocal Toric (sifilcon A) soft contact lenses are indicated for the optical correction of refractive ametropia (myopia, hyperopia, astigmatism and presbyopia) in phakic or aphakic persons with non-diseased eyes who may require a reading addition of +4.00 diopters (D) or less and have 4.00 diopters (D) or less of astigmatism.

The lenses may be prescribed for daily wear with removal for cleaning and disinfection (chemical, not heat) prior to reinsertion, as recommended by the eye care professional.

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)
Division of Ophthalmic Ear,
Nose and Throat Devices

510(k) Number

K062262

Prescription Use:

Over the Counter Use